首页|当归补血汤治疗肿瘤相关性贫血(脾肾两虚型)的临床研究及安全评价

当归补血汤治疗肿瘤相关性贫血(脾肾两虚型)的临床研究及安全评价

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
目的 分析当归补血汤治疗肿瘤相关性贫血(脾肾两虚型)的临床疗效及安全性.方法 随机数字表法将2020年9月—2023年6月潍坊医学院附属医院中医科收治的肿瘤相关性贫血(脾肾两虚型)患者70例分为两组,对照组(3 5例)采用促红细胞生成素(EPO)治疗,观察组(35例)在此基础上联合当归补血汤治疗,治疗4周后对比两组临床疗效、中医证候积分及卡诺夫斯基健康状况量表(KPS)评分贫血改善情况、T淋巴细胞水平、不良反应发生情况等.结果 观察组治疗总有效率为91.43％(32/35),远高于对照组的71.43％(25/35)(P＜0.05);治疗后观察组红细胞(RBC)、血红蛋白(Hb)、红细胞压积(HCT)、KPS评分高于对照组(P＜0.05);治疗后观察组中医症状积分低于对照组,CD4+、CD8+、低于对照组,CD4+/CD8+高于对照组(P＜0.05).两组不良反应比较差异无统计学意义(P＞0.05).结论 当归补血汤补气生血、益精填髓,用于治疗肿瘤相关性贫血(脾肾两虚型)患者能明显提高治疗效果,改善患者贫血情况,增强机体免疫功能,促进体力恢复,且不良反应少,对改善患者预后具有积极意义.
Clinical Study and Safety Evaluation of Danggui Buxue Decoction(当归补血汤)Treating Tumor-Associated Anemia(Spleen-Kidney Deficiency Type)
Objective To analyze the clinical efficacy and safety of Danggui Buxue Decoction(当归补血汤)in the treatment of tumor associated anemia(spleen-kidney deficiency type).Methods Seventy patients with tumor-related anemia(spleen-kidney deficiency)admitted from September 2020 to June 2023 were divided into two groups by random number table method.Thirty-five patients in the control group were treated with erythropoietin(EPO),and the other 35 patients in the observation group were treated with Danggui Buxue Decoction on this basis.After 4 weeks of treatment,the clinical efficacy,TCM syndrome score and Kanofsky Health Scale(KPS)score of anemia improvement,T lymphocyte level and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.43％(25/35),much higher than that of the control group(71.43％,25/35)(P＜0.05).After treatment,red blood cells(RBC),hemoglobin(Hb),hematocrit(HCT)and KPS scores in the observation group were higher than those in the control group(P＜0.05).After treat-ment,TCM symptom scores of the observation group were lower than those of the control group,the levels of CD4+and CD8+were lower than those of the control group,and the ration of CD4+/CD8+was higher than that of the control group(P＜0.05).There was no significant difference in adverse reactions between the two groups(P＞0.05).Conclusion Danggui Buxue Decoction for the treatment of tumor-related anemia(spleen and kidney deficiency type)can significantly improve the therapeutic effect and the anemia condition of patients,enhance the immune function,promote the physical recovery and has less adverse reactions,with positive significance for improving the prognosis of patients.

Danggui Buxue Decoction(当归补血汤)integrated traditional Chinese and western medicine therapyerythro-poietintumor-associated anemiaspleen-kidney deficiency type

刘玲素、王树庆

展开 >

潍坊医学院,山东潍坊 261053

潍坊医学院附属医院,山东潍坊 261031

当归补血汤 中西医结合疗法 促红细胞生成素 肿瘤相关性贫血 脾肾两虚型

国家中医药管理局科研基金项目山东省卫生健康委员会项目

00-01LP37Q-2022126

2024

10.13193/j.issn.1673-7717.2024.01.019

中华中医药学刊
中华中医药学会 ,辽宁中医药大学

中华中医药学刊

CSTPCD北大核心
影响因子：1.007
ISSN：1673-7717
年,卷(期)：2024.42(1)
  • 34